Pharmacovigilance – Products
Product News
Armis Biopharma Announces Receipt of a $20.3 Million Contract with the Defense Threat Reduction Agency to Develop Veriox® DECON for Battlefield Wounds
Armis Biopharma, Inc. announced that the company received a $20.3 million contract from the Defense Threat Reduction Agency (DTRA) to develop its proprietary Veriox® DECON chemical warfare agent (CWA) decontamination product.
Product News
OncoHost To Present Proteomics-Based Predictive Biomarker for Immune-Related Adverse Events in NSCLC Patients
Novel computational model accurately predicts significant irAEs in NSCLC patients based on proteomic profiling of one pre-treatment blood test.
Product News
Modelling Enables Breakthroughs in Neuromuscular Disease Research
A team of scientists have developed a protocol for the fabrication of a 3D microfluidic neuromuscular platform that can be used to model Motor Neuron Diseases (MND’s).
Product News
Lonza Further Extends Collaboration With Major Biopharmaceutical Partner for Manufacturing Antibody-Drug Conjugates
Extended long-term collaboration to provide significant additional bioconjugation capacity for commercialization of antibody-drug conjugates (ADCs) for use against hard-to-treat cancers.
Product
Advertisement
Seahorse XF MitoTox Assay Kit for Mitochondrial Toxicity and Drug Safety Evaluation
The Agilent Seahorse XF MitoTox assay kit allows for the direct functional measurements of mitochondrial oxygen consumption rates (OCR) and identification of drug-induced mitochondrial toxicity in drug safety evaluation studies
Product News
New Cell & Gene Therapy Solutions From Form Bio Analyze Billions of Potential Construct Candidates
Form Bio, announced capabilities for cell and gene therapy companies to rapidly model billions of potential construct candidates.
Product News
Kuano Raises £1.8M in Seed Funding to Accelerate Quantum Drug Discovery
Kuano, announced the close of its £1.8M seed funding round. The investment will facilitate further validation of Kuano’s quantum simulation platform for the design of more effective drug candidates targeting enzymes.
Product News
Novartis Kisqali® Reduced the Risk of Cancer Recurrence While Maintaining Quality of Life
Novartis presents new patient-reported outcomes (PRO) data from the Phase III NATALEE trial at the European Society for Medical Oncology (ESMO) Virtual Plenary.
Whitepaper
Antibody–Drug Conjugates: A Novel Paradigm for Cancer Therapy
This whitepaper highlights the key molecular components of ADCs and the challenges and opportunities for their future development.
Product
Advertisement
Influenza Vaccine Development and Production Solutions
Learn more about influenza vaccine solutions!
Advertisement